发明名称 |
HUMANIZED ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF |
摘要 |
The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment. |
申请公布号 |
US2014377284(A1) |
申请公布日期 |
2014.12.25 |
申请号 |
US201414221212 |
申请日期 |
2014.03.20 |
申请人 |
JANSSEN PHARMACEUTICALS, INC. ;BiocerOX Products B.V. |
发明人 |
SIMONS Petrus Johannes;BOON Louis;LUO Jinquan;BREZSKI Randall;GOLDBERG Monica |
分类号 |
C07K16/30 |
主分类号 |
C07K16/30 |
代理机构 |
|
代理人 |
|
主权项 |
1. An isolated antibody that binds human CD134, comprising a light chain variable region (VL) of SEQ ID NO: 100 and a heavy chain variable region (VH) comprising heavy chain complementarity determining regions (HCDR)s HCDR1, HCDR2 and HCDR3, optionally having 1, 2 or 3 amino acid substitutions in the VL of SEQ ID NO: 100. |
地址 |
Titusville NJ US |